New models developed at the Masonic Cancer Center, University of Minnesota reveal the genes and pathways that, when altered, can cause osteosarcoma. The information could be used to better target treatments for the often-deadly ...
May 27, 2015
0
5
(HealthDay)—Man's best friend will be part of an effort to find better treatments for a type of bone cancer in children and young adults, researchers report.
May 15, 2014
0
0
The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role ...
Apr 3, 2014
0
0
(Medical Xpress)—A gold-based drug currently used in human and veterinary medicine to manage certain immune diseases may prove useful in combating osteosarcoma, a devastating bone cancer that affects both dogs and people, ...
Mar 26, 2014
0
0
A genomewide association study (GWAS) has revealed two specific variations in the NFIB gene that may identify which children and adolescents with osteosarcoma have metastatic disease or are at high risk for metastasis, according ...
Nov 5, 2013
0
0
Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones.
Sep 28, 2013
0
0
Many cancers show inappropriate activation of a cell signaling pathway called NOTCH. In the developing body, NOTCH tells brain cells to grow and proliferate. It should be quiet in the adult body, but cancers restart NOTCH ...
Jul 23, 2013
0
0
Most of the time, it takes decades of accumulating genetic errors for a tumor to develop. While this explains the general occurrence of cancer in adults, it leaves a gap in understanding of the cause of pediatric tumors.
Jul 19, 2013
0
0
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track ...
Jun 20, 2013
0
0
(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric ...
Oct 16, 2012
0
0
